b Odds ratio was not calculated. P = 1.00 by Fisher's exact test.
Allogeneic hematopoietic SCT (HSCT) provides life-saving therapy for patients with hematologic malignancies or BM failure. Substantial morbidity results from immunosuppressive therapy administered to prevent GVHD. Post-transplant lymphoproliferative disorder (PTLD), an important complication of both HSC and solid organ transplantation, comprises a range of conditions from benign lymphoid hyperplasia to malignant lymphomas. 1 Following allogeneic HSCT, most PTLDs arise from donor B-cells. 1 EBV has a key role in lymphocyte transformation and is detectable in the majority of PTLD tumors. 1 We recently showed that solid organ transplant recipients frequently manifest elevated circulating levels of kappa and lambda free light chains (FLCs) detectable in peripheral blood (serum), and that FLC elevations are associated with an increased risk of subsequently developing PTLD. 2 FLCs are immunoglobulin fragments released by B-cells along with intact immunoglobulins. FLC levels are elevated in individuals with hepatitis C virus or autoimmune disease (groups with elevated lymphoma risk).
3,4 FLC levels are also predictive of development of non-Hodgkin lymphoma among people immunosuppressed due to human immunodeficiency virus infection. 5 In a second study that included both solid organ and allogeneic hematopoietic stem cell (HSC) recipients, 6 we demonstrated that some PTLD cases manifested a monoclonal FLC pattern, that is, a predominant excess only of circulating kappa or lambda FLC, yielding an abnormal FLC ratio. Such a pattern suggests production of one FLC by monoclonal PTLD tumor cells. However, we were unable to show convincing concordance of FLCs with light chains expressed by tumor cells, due to the small number of cases with tumor tissue available. Indeed, this study included only six PTLD cases among HSC recipients, and no other study has examined FLCs following HSCT.
In the present study, we sought to extend understanding regarding FLC levels among allogeneic HSC recipients. We assessed serum FLCs in 11 PTLD cases and 32 matched controls (allogeneic HSCT recipients without PTLD). 7 Conditioning was typically with fludarabine, busulfan and anti-thymocyte globulin, and some patients also received low-dose TBI. All PTLD cases were EBV-seropositive at transplantation. Sera were obtained on day 28 post transplant, before PTLD diagnosis in cases (median PTLD diagnosis at 48 days post transplant, range 28-580 days). FLCs were measured using previously described methods. 2 No recipient was administered i.v. Ig before serum sampling.
FLC abnormalities were common among allogeneic HSC recipients who did not develop PTLD (Table 1 ). In addition, three PTLD cases (27%) had an elevated kappa FLC level, and one of these also had an elevated lambda FLC level. No case had an abnormal kappa/lambda ratio, although case 969 had a ratio bordering the upper limit of normal (Table 2) . Overall, FLC levels were not associated with risk of developing PTLD (Table 1) .
While the associations with FLC levels were null, the sample size was quite small. Nonetheless, the results for the three PTLD cases with elevated FLCs are of interest (Table 2 ). These PTLDs arose 30-61 days post transplant, which tended to be earlier than for the eight PTLD cases without FLC abnormalities (median 41 vs 67 days post transplant, P = 0.38). Likewise, the intervals between serum sample draw date and PTLD onset were very short in the PTLD cases with FLC abnormalities (2-33 days) .
One of these cases warrants detailed description (case 969, Table 2 ). This 54-year-old patient presented with hepatosplenomegaly and lymphadenopathy at 30 days after allogeneic HSCT for chronic myelomonocytic leukemia. EBV viremia was detected, and the patient was treated with rituximab. The serum sample evaluated for this patient, obtained only 2 days before presentation, showed the greatest elevation in kappa FLC among our study subjects (1.70 × upper limit of normal), and as noted above, the kappa/lambda ratio of 1.57 was borderline elevated. These results suggest the presence of a monoclonal excess of kappa FLC. A lymph node obtained at biopsy on post-transplant day 49 (after rituximab treatment) was consistent with polymorphic PTLD. The node exhibited loss of cortical B-cell follicles, while the remaining paracortical zone comprised a mixed cell population, predominantly T cells, but also containing CD20 − CD138+ MUM1+ plasmacytoid B-cells expressing an excess of kappa light chain. A minority of lymphoid cells showed nuclear staining for EBV.
Transplant-related immunosuppression mainly involves depressed T-cell function, and these deficits facilitate EBV-driven lymphoproliferation. Disordered B-cell function is also present 8 and probably contributes to the development of PTLD. Circulating monoclonal Ig proteins (that is, M-proteins) are common in HSC recipients 9, 10 and, like FLCs, may derive from plasma cells or EBV-activated B-cells. In both solid organ and allogeneic HSC recipients, FLC levels are positively associated with EBV viral load levels. 2, 6 The relationships between FLC elevations and PTLD, observed in this study and others, 2, 6 may have two explanations that are not mutually exclusive. First, elevated FLC levels could reflect generalized B-cell activation. In the present study, sera were obtained in the first month post transplant. At this early time point, donor B-cells are usually undetectable, and antibody levels largely reflect Ig produced by recipient plasma cells. 8 Because most PTLDs develop later from donor B-cells, associations with FLCs may have been blunted in our study.
A second explanation is that, in some cases, a predominant excess of kappa or lambda FLC may be produced by a single neoplastic B-cell clone. Under this model, in which a monoclonal FLC excess serves as a tumor marker, associations would be strongest for samples obtained shortly before clinical diagnosis, and the light-chain restriction of the PTLD tumor cells should match the FLC excess. The three cases described in Table 2 , especially case 969, may represent examples of this mechanism.
In our prior report based on larger numbers, 6 several patients exhibited changes in FLC levels with PTLD treatment, supporting that FLCs may also provide information on disease burden. Additional research is needed to understand the biological implications of FLC abnormalities in transplant recipients. 
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